News for CUBT Stock

Curative Biotechnology, Inc. Engages Golden Eagle Capital Advisors, Inc. as Exclusive Agent and Strategic Advisor Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors Curative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions Curative Biotechnology, Inc. Files Patent on Ophthalmic Formulation Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study Curative Biotechnology Announces Intent to Uplist to NYSE American Exchange Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors Curative Biotechnology, Inc. Names Cary Sucoff to Board of Directors Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors Curative Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies with Metformin Eye Drop Formulations for Treatment of Macular Degeneration Curative Biotechnology Announces Cooperative Research and Development Agreement(CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular Degeneration Curative Biotechnology Announces Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular Degeneration [UPDATED] CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN COVID-19 VACCINE Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board Curative Biotechnology, Inc. Appoints Marc Drimer, CPA to Board of Directors as Independent Director and Chairman of Audit Committee Curative Biotechnology, Inc. Files 2021 First Quarter Financials and Issues Letter to Shareholders Curative Biotechnology, Inc. Announces Trading Symbol Change to “CUBT” Curative Biotechnology, Inc. Announces FINRA Ticker Symbol Change From "CTYX" To "CUBT"